Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Releases DTC Guidances; "Not The Last Word" On Ads, Commissioner McClellan Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency pledges further review of its guidance on direct-to-consumer advertising. Broadcast ads for drugs and enforcement actions against repeat offenders could see more attention.

You may also be interested in...



FDA To Investigate Role Of Context Of Risk Information In DTC Print Ads

Agency will undertake two consumer studies to determine possible options for improving communication of risk information in ads.

FDA To Investigate Role Of Context Of Risk Information In DTC Print Ads

Agency will undertake two consumer studies to determine possible options for improving communication of risk information in ads.

WLF’s “DDMAC Watch” Objects To Vitrase Ad Division Letter

Including the full risk information in the “brief summary” portion of promotional materials is sufficient, Washington Legal Foundation says.

Related Content

Topics

UsernamePublicRestriction

Register

PS058751

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel